Mr. Todd Shapiro reports

RED LIGHT HOLLAND ANNOUNCES FILAMENT HEALTH'S PEX010 DRUG CANDIDATE, THE STANDARDIZED AND PATENTED NATURAL PSILOCYBIN TRUSTED ACROSS 80+ STUDIES GLOBALLY, SELECTED BY UCSF FOR STUDY PROBING PRECLINICAL ALZHEIMER'S MARKERS

Following Red Light Holland Corp.'s acquisition of Filament Health Corp., the company has expanded its pharmaceutical-grade manufacturing, regulatory and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

• Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.

The company is pleased to announce a newly signed agreement to supply PEX010 to the University of California, San Francisco (UCSF), reflecting the continued selection of Filament's standardized natural psilocybin by leading academic institutions.

Under the new agreement, Filament will supply its PEX010 botanical psilocybin drug candidate to UCSF, located in San Francisco, Calif., for a double-blind, randomized trial investigating the safety, feasibility and mechanisms of psychedelics in healthy older adults with low well-being, as moderated by biomarkers for preclinical Alzheimer's disease.

Among its objectives, the study is designed to examine whether a single dose of psilocybin can influence plasma markers of neuroinflammation over time, alongside acute changes in brain electrical activity measured by EEG and longitudinal structural and functional changes measured by MRI. Neuroinflammation is increasingly studied as a contributor to mood, cognition and neurodegenerative processes, including the earliest stages of Alzheimer's disease.

This development reflects continued demand for pharmaceutical-grade, naturally derived psilocybin and the expanding role of Filament Health's PEX010 in academic and clinical research, while reinforcing the operational and quality systems that support reliable global supply. The study is independently sponsored and conducted by UCSF and its investigators, with Filament supplying PEX010 as the investigational drug product.

PEX010 is produced using Filament's proprietary extraction and stabilization methods, which deliver a potent yet standardized and patented botanical drug product with consistent composition across every study and every research site.

"What sets us and PEX010 apart is consistency and regulatory excellence of our proprietary extraction and stabilization methods," said Todd Shapiro, chief executive officer and director of Red Light. "The reliability of PEX010 allows the world's best researchers to keep pushing psychedelic science to new boundaries. The UCSF study is a perfect example, exploring whether a single dose of psilocybin can influence neuroinflammatory markers in the aging brain. That kind of subtle science is only possible with a drug product investigators can trust dose after dose, which is why PEX010 has now been selected for more than 80 studies worldwide."

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. On April 30, 2026, Red Light completed its previously announced acquisition of Filament Health, including its portfolio of 76 issued patents across 15 patent families and its lead drug candidate, PEX010, creating a global leader in psychedelic drug development, commercialization and distribution.

About Red Light Holland Corp.

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and R&D (research and development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Holland Corp.

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.

We seek Safe Harbor.